-
In the past half century, technology, environmental awareness, and modern science have surged. Yet, as in all generations, a significant number of consumers, perhaps intent upon getting back to simpler times, are choosing "healthful" therapies not fully accepted by the mainstream.
-
To review the evidence supporting indications for inductions of labor.
-
Almost one-fifth of Medicare patients who were discharged from a hospital were rehospitalized within 30 days, and about a third were rehospitalized within 90 days. Most of these readmissions were not planned.
-
When 4 different interfaces with varying internal dead space were randomly applied during non-invasive ventilation in 14 patients with acute respiratory failure, there were no significant differences in gas exchange, minute ventilation, or work of breathing, but patient tolerance of the different devices varied substantially.
-
The introduction of drug-eluting stents (DES) was met with enthusiasm from the interventional cardiology community because of the dramatic reduction in rates of in-stent restenosis (ISR). However, it came to be recognized that this clinical benefit, due to reduced proliferation of smooth muscle cells, came at a price.
-
This study showed that surrogate decision-makers with a loved one in the ICU want clinicians to discuss the patient's prognosis, even if it is uncertain.
-
Timsit et al conducted a 2x2 randomized, controlled trial comparing chlorhexidine-impregnated sponges in the dressing of vascular catheters with control dressings.
-
-
Patients presenting to the emergency department (ED) with acute chest pain are a significant portion of our health care budget. Current recommendations for the assessment and management of these patients involve extended periods of observation for repeated biomarkers and electrocardiograms (ECG). This often results in hospital admission to "rule out" myocardial infarction. Any advance in the speed or accuracy of diagnosis of the cause of chest pain, or to rule out myocardial ischemia as the cause, would be a significant clinical advance.
-
NSAIDs in the elderly; managing GI and CVD risk with NSAIDs; low-dose naltrexone and fibromyalgia; treating glucocorticoid-induced bone loss; FDA Actions.